Know Cancer

forgot password

A Randomized, Phase III Clinical Trial to Compare Sentinel Node Resection to Conventional Axillary Dissection in Clinically Node-Negative Breast Cancer Patients

Phase 3
18 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

A Randomized, Phase III Clinical Trial to Compare Sentinel Node Resection to Conventional Axillary Dissection in Clinically Node-Negative Breast Cancer Patients


- Compare the long term control of regional disease by sentinel node resection vs
sentinel node resection followed by conventional axillary dissection in women with
breast cancer who are clinically node negative and pathologically sentinel node

- Compare the effect of these two regimens on the overall and disease-free survival of
these patients.

- Compare the morbidity associated with these two regimens in these patients.

- Compare the prognostic value of these two regimens in patients who are sentinel node
negative or positive by pathology.

- Determine whether a more detailed pathology investigation can identify a group of
patients with a potentially increased risk of systemic recurrence who are node negative
by pathology.

- Determine the technical success rate of sentinel node dissection and the variability of
technical success rate in a broad population of surgeons.

- Determine the sensitivity of the sentinel node to determine the presence of nodal
metastases in these patients.

Objectives of quality of life questionnaire in sentinel node-negative patients:

- Compare the severity of self-assessed symptoms and activity limitations of patients
treated with these two regimens.

- Compare the severity of self-assessed symptoms and activity limitations after breast
cancer surgery in patients whose surgery was on the dominant side vs patients whose
surgery was on the non-dominant side.

- Compare the impact of arm edema, range of motion, and sensory neuropathy on
self-assessed measures of daily functioning, symptoms, and overall quality of life of
patients treated with these regimens.

OUTLINE: This is a randomized study. Patients are stratified according to the surgical
treatment plan (lumpectomy vs mastectomy), age (49 and under vs 50 and over), and clinical
tumor size (no greater than 2.0 cm vs 2.1-4.0 cm vs at least 4.1 cm). Patients are
randomized to one of two surgery arms.

All patients receive technetium (Tc 99m) sulfur colloid injected into normal breast tissue
within 1 cm of the primary tumor or biopsy cavity and an intradermal injection of technetium
(Tc 99m) sulfur colloid, approximately 0.5-8 hours before surgery. Patients also receive an
injection of isosulfan blue dye around the tumor or biopsy cavity after a hot spot is
identified with a gamma detector. If a hot spot is not identified, the blue dye is injected
after a saline bolus injection.

- Arm I: Patients undergo sentinel node resection immediately followed by conventional
axillary dissection.

- Arm II: Patients undergo sentinel node resection and an intraoperative examination of
sentinel nodes.

Patients with positive sentinel nodes undergo axillary dissection after sentinel node

Patients with cytologically negative sentinel nodes do not undergo axillary dissection.

Patients with cytologically negative but histologically positive sentinel nodes return to
surgery for axillary dissection.

Patients with histologically positive sentinel nodes and those in whom the sentinel node is
not identified undergo axillary dissection after sentinel node resection.

Patients with pathologically positive, nonaxillary sentinel nodes undergo axillary
dissection after sentinel node resection.

Patients with evidence of tumor remaining after surgery undergo a total mastectomy.

Quality of life is assessed at baseline, at weeks 1-3, and then every 6 months for 3 years
or until recurrence.

Patients are followed at 1 and 3 weeks, every 6 months for 3 years, and then annually

PROJECTED ACCRUAL: Approximately 5,400 patients will be accrued for this study within 4

Inclusion Criteria


- Resectable invasive adenocarcinoma of the breast, confirmed by 1 of the following:

- Histologically confirmed by core or open biopsy

- Confirmed by fine needle aspiration cytology AND positive clinical breast
examination and ultrasound or mammography

- Clinically negative lymph nodes

- No positive ipsilateral axillary lymph nodes

- No prior removal of ipsilateral axillary lymph nodes

- No suspicious palpable nodes in the contralateral axilla or palpable
supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy

- No ulceration, erythema, infiltration of the skin or underlying chest wall (complete
fixation), peau d'orange, or skin edema of any magnitude

- Tethering or dimpling of the skin or nipple inversion allowed

- No bilateral malignancy or mass in the opposite breast that is suspicious for
malignancy, unless proven nonmalignant by biopsy

- No diffuse tumors or multiple malignant tumors in different quadrants of the breast

- No other prior breast malignancy except lobular carcinoma in situ

- No prior or concurrent breast implants

- Hormone receptor status:

- Not specified



- 18 years and older


- Female

Menopausal status:

- Not specified

Performance status:

- Not specified

Life expectancy:

- At least 10 years (excluding diagnosis of cancer)


- Not specified


- No hepatic systemic disease


- No renal systemic disease


- No cardiovascular systemic disease


- No prior malignancy within past 5 years except:

- Effectively treated squamous cell or basal cell skin cancer

- Surgically treated carcinoma in situ of the cervix

- Surgically treated lobular carcinoma in situ of the ipsilateral or contralateral

- No concurrent psychiatric or addictive disorder


Biologic therapy:

- No prior immunotherapy for this cancer


- No prior chemotherapy for this cancer, including neoadjuvant chemotherapy

Endocrine therapy:

- No prior hormonal therapy for this cancer


- No prior radiotherapy for this cancer


- See Disease Characteristics

- No prior breast reduction surgery

- Prior excisional biopsy or lumpectomy allowed

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Morbidity as measured by arm edema, sensory neuropathy, and arm function - mobility

Outcome Time Frame:

Before and after surgery

Safety Issue:


Principal Investigator

Norman Wolmark, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

NSABP Foundation, Inc.


United States: Federal Government

Study ID:




Start Date:

May 1999

Completion Date:

December 2013

Related Keywords:

  • Breast Cancer
  • stage I breast cancer
  • stage II breast cancer
  • Breast Neoplasms



Akron City Hospital Akron, Ohio  44304
Ireland Cancer Center Cleveland, Ohio  44106-5065
CCOP - Upstate Carolina Spartanburg, South Carolina  29303
CCOP - Wichita Wichita, Kansas  67214-3882
University of Texas Health Science Center at San Antonio San Antonio, Texas  78284-7811
CCOP - Kansas City Kansas City, Missouri  64131
CCOP - Mount Sinai Medical Center Miami Beach, Florida  33140
CCOP - Southeast Cancer Control Consortium Winston-Salem, North Carolina  27104-4241
MBCCOP - Massey Cancer Center Richmond, Virginia  23298-0037
CCOP - Illinois Oncology Research Association Peoria, Illinois  61602
CCOP - Iowa Oncology Research Association Des Moines, Iowa  50309-1016
CCOP - Kalamazoo Kalamazoo, Michigan  49007-3731
Methodist Cancer Center at Methodist Hospital Indianapolis, Indiana  46202
CCOP - Michigan Cancer Research Consortium Ann Arbor, Michigan  48106
Geisinger Medical Center Danville, Pennsylvania  17822-0001
Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin  53226
CCOP - Merit Care Hospital Fargo, North Dakota  58122
Comprehensive Cancer Center at Wake Forest University Winston-Salem, North Carolina  27157-1082
Huntsman Cancer Institute Salt Lake City, Utah  84112
Halifax Medical Center Daytona Beach, Florida  32114
CCOP - Montana Cancer Consortium Billings, Montana  59101
Newark Beth Israel Medical Center Newark, New Jersey  07112
CCOP - Columbus Columbus, Ohio  43206
CCOP - Dayton Kettering, Ohio  45429
Reading Hospital and Medical Center Reading, Pennsylvania  19612-6052
CCOP - MainLine Health Wynnewood, Pennsylvania  19096
CCOP - Northern Indiana CR Consortium South Bend, Indiana  46601
CCOP - Grand Rapids Grand Rapids, Michigan  49503
Charles M. Barrett Cancer Center at University Hospital Cincinnati, Ohio  45267-0526
CCOP - Columbia River Oncology Program Portland, Oregon  97225
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia Philadelphia, Pennsylvania  19107
Baptist Regional Cancer Institute - Jacksonville Jacksonville, Florida  32207
Cancer Research Center of Hawaii Honolulu, Hawaii  96813
MBCCOP - Gulf Coast Mobile, Alabama  36688
University of Arkansas for Medical Sciences Little Rock, Arkansas  72205
CCOP - Northwest Tacoma, Washington  98405-0986
Puget Sound Oncology Consortium Seattle, Washington  98109
Hartford Hospital Hartford, Connecticut  06102-5037
Sarasota Memorial Hospital Sarasota, Florida  34239
MBCCOP-Cook County Hospital Chicago, Illinois  60612
Eastern Maine Medical Center Bangor, Maine  04401
Franklin Square Hospital Center Baltimore, Maryland  21237
Michigan State University East Lansing, Michigan  48824
Allegheny General Hospital Pittsburgh, Pennsylvania  15212-4772
Utah Valley Regional Medical Center - Provo Provo, Utah  84604
Virginia Oncology Associates - Newport News Newport News, Virginia  23606
Cancer Institute of New Jersey New Brunswick, New Jersey  08901
Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego San Diego, California  92120
University of Massachusetts Memorial Medical Center - University Campus Worcester, Massachusetts  01655
City of Hope Comprehensive Cancer Center Duarte, California  91010
CCOP - Beaumont Royal Oak, Michigan  48073-6769
Cancer Research Center at Boston Medical Center Boston, Massachusetts  02118
Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan  48202
Stanford Cancer Center at Stanford University Medical Center Stanford, California  94305
Loma Linda University Cancer Institute at Loma Linda University Medical Center Loma Linda, California  92354
Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha Omaha, Nebraska  68114-4199
Aultman Hospital Cancer Center at Aultman Health Foundation Canton, Ohio  44710-1799
Vermont Cancer Center at University of Vermont Burlington, Vermont  05405-0075
MBCCOP - Howard University Cancer Center Washington, District of Columbia  20060
Creticos Cancer Center at Advocate Illinois Masonic Medical Center Chicago, Illinois  60657
Providence Cancer Institute at Providence Hospital Southfield, Michigan  48075
University of Miami Sylvester Cancer Center Miami, Florida  33136
Stanley S. Scott Cancer Center at Louisiana State University Medical Center - New Orleans New Orleans, Louisiana  70112
Tulane University Medical Center New Orleans, Louisiana  70112
New York Oncology Hematology, P.C. - Albany Regional Cancer Center Albany, New York  12208
Jewish Hospital of Cincinnati, Incorporated Cincinnati, Ohio  45236
Sutter Breast Cancer Group Sacramento, California  95819-5156
Camcare Health Charleston, West Virginia  25304